The cystic fibrosis transmembrane conductance regulator (CFTR) 
The gene involved in cystic fibrosis (CF), the most common genetic disease among white populations, has been isolated and sequenced. '-3 The protein encoded by this gene, named cystic fibrosis transmembrane conductance regulator (CFTR), contains 1480 amino acids, has two membrane associated domains, two ATP binding folds (NBF), and a large highly charged domain (R) containing phosphorylation sites for protein kinases A and C. The most common mutation responsible for CF is a deletion, in exon 10 (first NBF domain), of a triplet coding for a phenylalanine at position 508 
Results

THE AF508 MUTATION
The CFTR gene analysis presented here shows that among the 1200 CF chromosomes tested, 827 (69%) carry the AF508 mutation and 373 (31%) carry another mutation: 310 patients (51-5%) are AF508 homozygotes, 207 patients (34 5%) are compound heterozygotes for AF508 and another mutation, and 83 patients (14%) have two other mutations.
SCREENING FOR OTHER MUTATIONS
The 104 other mutations tested are located in 14 different PCR products corresponding to 14 exons and their splice junctions. At the beginning of this work, the choice of regions to study was influenced by the number of mutations described and their frequency. Then with the rapid increase in the number of mutations identified, the choice was influenced by the origin of the population.
Among the 104 other CFTR mutations tested on the 373 non-AF508 CF chromosomes, none of the following 58 mutations were found: G91R, 435 This study underlines some other factors. The identification of R334W in two affected sibs and the study of the segregation of this mutation through the family showed that the mother, without a history of CF, was homozygous for R334W. Further clinical investigations showed that she had a positive sweat test (80 mmol/l) and was pancreatic sufficient. This mutation has previously been described as a "mild" mutation.24
As reported by Kalin et al,25 the two CF chromosomes (from unrelated patients) positive for S1251N also carry the polymorphism F508C,26 but two other CF chromosomes bearing F508C are negative for S1251N and have unknown mutations.
The splice mutation 711 + 1G-+T, first described with a high frequency in CF families living in Quebec,27 was found in three homozygous and two compound heterozygous patients originating from North Africa. This mutation, also associated with haplotype A, accounts for 5% of CF chromosomes in this population and most of the other North African CF chromosomes carry unidentified mutations.
In our study, W1282X has a higher frequency than in the rest of France (CFGAC). This mutation has been reported with a high frequency (60% of CF chromosomes) in the Ashkenazi Jewish population. 28 The cause of this frequency in our sample is unknown as the origin of these 18 chromosomes is variable (from the north east to south east of France).
The mutation 3905 insT, described with a frequency of about 9% in Swiss CF chromosomes29 has been found in our study in a large gypsy population where it is associated with AF508.
Discussion
The present study gives a representative view of the frequency of 105 CF mutations in an important sample of the CF population (600 patients).
From our data, the molecular pathology of the CFTR gene is exceedingly heterogeneous in our population: only 86% of the CF alleles identified with 47 different mutations (out of 105 tested). Most of the unidentified mutations are probably very rare and almost "private", so that systematic sequencing of these chromosomes would be necessary, but this procedure represents an unrewarding amount of work.
Most of the identified CF alleles belong to haplotype B (96%), while only 62% of groups A and D and 46% of groups C were identified. Consequently, for the patients with non-B chromosomes, polymorphism study (RFLP and microsatellites) will be necessary to identify the heterozygotes and allow prenatal diagnosis for the family. At the end of this study, mutation and haplotype analysis made 98 5% of the families informative. Besides informativeness, the identification of the most frequent mutations in a given population is necessary for genetic counselling for at risk couples when one of the partners is a proven heterozygote. For the other partner, who has an initial risk of being a carrier of 1 in 25, the screening of the seven mutations AF508, G542X, N1303K, W1282X, 1717-1G-+A, 2184delA+2183A-.G, and R553X allows a better estimation of this risk; it drops to 1 in 120 if this screening is negative.
Our data also indicate that the goal of population screening for CF mutations (identification of 90 to 95% of the CF alleles) will be very difficult in this population of mixed ancestry because many different mutations will have to be tested. It seems very unlikely that a frequent but still unknown mutation will be identified, as many European CF chromosomes have already been sequenced.
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